Drug Combination Details
| General Information of the Combination (ID: C92614) | |||||
|---|---|---|---|---|---|
| Name | Vincristine NP Info | + | BI-D1870 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Acute myeloid leukemia
[ICD-11: 2A60]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Biological
Regulation |
Induction | Cell cycle arrest in M phase | ||||
| In-vitro Model | KG-1 | CVCL_0374 | Adult acute myeloid leukemia | Homo sapiens | ||
| HL-60 | CVCL_0002 | Adult acute myeloid leukemia | Homo sapiens | |||
| NALM-6 | CVCL_0092 | Adult B acute lymphoblastic leukemia | Homo sapiens | |||
| Experimental
Result(s) |
BI-D1870 induces apoptosis of AML cells alone and in combination with vincristine through blocking mitotic exit, providing a novel approach to overcoming vincristine resistance in AML cells. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | RSK inhibitor BI-D1870 inhibits acute myeloid leukemia cell proliferation by targeting mitotic exit. Oncotarget. 2020 Jun 23;11(25):2387-2403. | |||
